Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Prolixin
Published 2025-12-22 · Last reviewed 2025-12-29 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Fluphenazine is a high-potency first-generation antipsychotic (FGA) available in oral and depot formulations for schizophrenia maintenance, offering potent D2 blockade with minimal metabolic burden.
Depot fluphenazine decanoate remains a cost-effective option when long-acting coverage is needed and extrapyramidal risk can be managed.
The compare view and fluphenazine evidence feed can help contrast EPS liability, metabolic effects, and LAI intervals when switching depot strategies.
Depot planning can be supported by the LAI Navigator and the schizophrenia hub; injection counseling can be shared via the fluphenazine print page.
Best suited to patients who have previously responded to FGAs and can engage in routine movement-disorder monitoring; generally avoided for behavioral symptoms in dementia, and therapy is reassessed if tardive dyskinesia emerges.
Used for maintenance in resource-limited settings and for patients responsive to typical antipsychotics; EPS prophylaxis and tardive dyskinesia monitoring are key safety considerations.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
High-affinity antagonist at dopamine D2 receptors suppressing psychotic symptoms while increasing extrapyramidal risk.
Limited serotonergic antagonism and minimal histaminergic or muscarinic blockade produce lower sedation and anticholinergic burden than low-potency FGAs.
Monitoring prioritizes movement disorders and depot logistics; the LAI format can improve adherence but also makes side effects slower to reverse, so early detection matters.